HTB | HIV i-Base

Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer

Featured AIDS quilts at the Tate: reflection and also anger 8 July 2025. Related: In memory, Early access, Special reports.
Featured UK HIV care for transgender and non-binary people: EHRC guidance is unworkable 1 July 2025. Related: Special reports, Treatment access, Activism & advocacy.
Featured Latest news on the US crisis and its impact on global health 1 June 2025. Related: Journal scan, Special reports, Treatment access, Activism & advocacy.
Featured Reduced dosing: a possible crisis response to ART stockouts and closed clinics 5 May 2025. Related: Special reports, Antiretrovirals, Treatment strategies, Treatment access.
Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks 17 July 2025. Related: Early access, Conference reports, Antiretrovirals, Drug resistance, IAS 13th Kigali 2025.
Potential for once-monthly oral PrEP using MK-8527 17 July 2025. Related: Early access, Conference reports, Treatment strategies, IAS 13th Kigali 2025.
Five doses a week could be a safe option for adults: crisis response to ART stock-outs 16 July 2025. Related: Early access, Conference reports, Treatment strategies, IAS 13th Kigali 2025.
5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no difference in clinical outcomes 16 July 2025. Related: Early access, Conference reports, Treatment strategies.
Signal that sliver of PEPFAR might be salvaged 16 July 2025. Related: Early access, Treatment access.
IAS 2025: “We will not be erased” – a community Call to Action 15 July 2025. Related: Early access, Conference reports, Treatment access, Activism & advocacy, IAS 13th Kigali 2025.
Call to drop abacavir from use in adults 13 July 2025. Related: Journal scan, Antiretrovirals, Treatment strategies, Coinfections and complications.
13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports 13 July 2025. Related: Early access, Conference reports, Activism & advocacy, Conference index, IAS 13th Kigali 2025.
IAS 2025: HIV care is political: early focus on the funding crisis 12 July 2025. Related: Conference reports, Treatment access, IAS 13th Kigali 2025.
HIV cure research at IAS 2025 12 July 2025. Related: Early access, Conference reports, IAS 13th Kigali 2025.
Global Fund plans for lenacapavir PrEP in selected countries 9 July 2025. Related: Early access, Treatment access, HIV prevention and transmission.
US government has altered more than 100 scientific databases since 20 January 5 July 2025. Related: Early access, Treatment alerts, Activism & advocacy.
Latest news on US crisis (3 July): legal challenges, Global Fund, WHO, Kigali conference 5 July 2025. Related: Treatment access, Activism & advocacy.
Clinical phase 2/3 studies put on hold for two once-weekly pipeline compounds 3 July 2025. Related: Antiretrovirals.
UK PrEP 2025 guidelines online 2 July 2025. Related: Guidelines, HIV prevention and transmission.
Why the new HIV PrEP guidelines from the UK are so exciting (2025) 2 July 2025. Related: Special reports, Guidelines, HIV prevention and transmission.
Latest on US crisis (26 June): Global Fund, GAVI and RFK Jr 2 July 2025. Related: Treatment access, Activism & advocacy.
Long-acting injectable PrEP approved in the US: priced at $28,000 a year 1 July 2025. Related: Antiretrovirals, HIV prevention and transmission.
Future meetings and webinars 2025 1 July 2025. Related: Future meetings.
Latest on US crisis (13 June): legal and organisational responses 1 July 2025. Related: Treatment access, Activism & advocacy.
HIV organisations support trans and non-binary communities against the unworkable EHRC guidance 1 July 2025. Related: Treatment access, Activism & advocacy.
Kigali Call to Action: sign-on for IAS 2025 conference 1 July 2025. Related: Conference reports, IAS 13th Kigali 2025.
UK guidelines on doxyPEP to prevent syphilis and gonorrhoea vaccine to become available in England 17 June 2025. Related: Guidelines, Coinfections and complications.
APBI calls for greater participant diversity in industry studies 15 June 2025. Related: Activism & advocacy, Research studies.
Risk of metabolic syndrome when starting ART with bictegravir vs dolutegravir 7 June 2025. Related: Journal scan, Side effects, Weight, diabetes, metabolic complications.
TAG challenges HIV vaccine cuts as Robert F. Kennedy fires entire CDC vaccine expert advisory panel 6 June 2025. Related: Treatment access, Activism & advocacy, Research studies.
Gates Foundation commits to providing lenacapavir as PrEP next year 3 June 2025. Related: Treatment access, HIV prevention and transmission.
IAS-USA update drug resistance mutations (2025) 29 May 2025. Related: Guidelines, Drug resistance.
Vaccination is effective in limiting mpox progression – but lower efficacy in people living with HIV 27 May 2025. Related: Journal scan, mpox.
US updates guidelines for statin use in people living with HIV 26 May 2025. Related: Guidelines, Weight, diabetes, metabolic complications.
HIV activists in the US call for action in JID and Zachie Achmat brings South African perspective in the Lancet 26 May 2025. Related: Journal scan, Treatment access, Activism & advocacy.
Combining injectable lenacapavir and cabotegravir-LA 23 May 2025. Related: Journal scan, Antiretrovirals, Treatment strategies, Treatment access.
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement 22 May 2025. Related: Treatment access, Activism & advocacy, Research studies.
Impact of US funding cuts in Malawi and South Africa: ITPC community report 20 May 2025. Related: Treatment access, On the web.
The Denver Principles – riso print by Jane Shepherd to support i-Base 17 May 2025. Related: Special reports.
US CDC updated guidelines on PEP (May 2025) 10 May 2025. Related: Guidelines, HIV prevention and transmission.
Closed clinics and limited ART in Zimbabwe, PEPFAR and UNAIDS news 4 May 2025. Related: Treatment access, Activism & advocacy.
Yellow card reporting scheme for doctors and patients in the UK 1 May 2025. Related: Side effects.
The RIO study: Q&A about controlling HIV with bNAbs 21 April 2025. Related: Conference reports, Cure-related research, CROI 32 San Francisco 2025.
Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years 20 April 2025. Related: Antiretrovirals, Treatment access, Drug resistance, BHIVA news.
CROI 2025: Webcasts and other resources now open access 16 April 2025. Related: Conference reports, CROI 32 San Francisco 2025.
Continued reports from CROI 2025 13 April 2025. Related: Conference reports, Conference index, CROI 32 San Francisco 2025.
Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs 13 April 2025. Related: Journal scan, Treatment strategies, Drug resistance.
CROI 2025: LAPTOP, EC rebounds after 32 years, two more HSCT cures 12 April 2025. Related: Conference reports, Antiretrovirals, Treatment strategies, CROI 32 San Francisco 2025.
Lancet Commission on gender justice and equality 9 April 2025. Related: Journal scan.
Changes to US policy jeopardises the lives of 500,000 children living with HIV by 2030 8 April 2025. Related: Treatment access.